(ARGX) Argen-X - Ratings and Ratios
Therapies, Treatments, Medicines, Autoimmune, Diseases
ARGX EPS (Earnings per Share)
ARGX Revenue
Description: ARGX Argen-X
Argen-X (BR:ARGX) is a commercial-stage biopharma company that develops therapies for treating autoimmune diseases. The company has a strong product pipeline, with VYGART and VYGART HYTRULO already approved for treating generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).
The companys product pipeline includes efgartigimod, empasiprubart, and ARGX-119, which are being developed for various indications, including seronegative and ocular gMG, thyroid eye diseases, myositis, Sjögrens disease, lupus nephropathy, and amyotrophic lateral sclerosis. Argen-X also has a robust research and development program, with multiple candidates in various stages of development, including ARGX-109, ARGX-121, ARGX-213, and ARGX-118.
From a financial perspective, Argen-X has a market capitalization of approximately €28.98 billion, with a price-to-earnings ratio of 33.60 and a forward price-to-earnings ratio of 54.95. The companys return on equity is 24.42%, indicating a strong ability to generate profits from shareholder equity. Key performance indicators (KPIs) to watch include revenue growth, R&D expenses as a percentage of revenue, and the number of patients treated with VYGART and VYGART HYTRULO.
Argen-X has established strategic collaborations with multiple partners, including OncoVerity, LEO Pharma, Zai Lab, AbbVie, and Genmab, among others. These partnerships can help accelerate the development and commercialization of the companys products, potentially driving future growth and revenue. Investors should monitor the progress of these partnerships and the companys ability to execute on its development plans.
To further evaluate Argen-Xs potential, investors can analyze additional KPIs, such as the companys cash runway, the number of upcoming milestones, and the competitive landscape for its products. A thorough analysis of these factors can help investors make a more informed decision about the companys potential for future growth and returns.
Additional Sources for ARGX Stock
ARGX Stock Overview
| Market Cap in USD | 33,717m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2017-05-18 |
ARGX Stock Ratings
| Growth Rating | 60.3 |
| Fundamental | 63.5 |
| Dividend Rating | 0.0 |
| Rel. Strength | 31.2 |
| Analysts | - |
| Fair Price Momentum | 483.91 EUR |
| Fair Price DCF | - |
ARGX Dividends
Currently no dividends paidARGX Growth Ratios
| Growth Correlation 3m | -78.1% |
| Growth Correlation 12m | 16.4% |
| Growth Correlation 5y | 90.4% |
| CAGR 5y | 15.40% |
| CAGR/Max DD 5y | 0.39 |
| Sharpe Ratio 12m | 1.03 |
| Alpha | 9.23 |
| Beta | 0.098 |
| Volatility | 32.95% |
| Current Volume | 68.7k |
| Average Volume 20d | 74.6k |
| Stop Loss | 475.9 (-3%) |
As of July 19, 2025, the stock is trading at EUR 490.80 with a total of 68,657 shares traded.
Over the past week, the price has changed by +1.11%, over one month by +3.81%, over three months by -6.37% and over the past year by +15.92%.
Yes, based on ValueRay´s Fundamental Analyses, Argen-X (BR:ARGX) is currently (July 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 63.54 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARGX is around 483.91 EUR . This means that ARGX is currently overvalued and has a potential downside of -1.4%.
Argen-X has no consensus analysts rating.
According to our own proprietary Forecast Model, ARGX Argen-X will be worth about 522.6 in July 2026. The stock is currently trading at 490.80. This means that the stock has a potential upside of +6.49%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 666.3 | 35.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 522.6 | 6.5% |